McDonnell Boehnen Hulbert & Berghoff LLP partner Dr. Kevin E. Noonan is quoted in a September 20, 2017 edition of BioWorld in an article entitled, “Flaws in the IPR process give rise to some very inventive patent solutions.” Before making a mad dash to follow Allergan plc’s lead in handing off key patents to an Indian tribe to avoid inter partes reviews (IPRs), other drug and med-tech companies may want to watch from the sidelines to see how the U.S. Supreme Court rules in a case that could doom the entire IPR process. View the article